Bone metastasis radiotherapy trials still omit essential pain-response assessment details
Among 39 palliative bone radiotherapy studies, 33% omitted the pain metric and 51% omitted the recall period.
Among 39 palliative bone radiotherapy studies, 33% omitted the pain metric and 51% omitted the recall period.
External-beam and radiopharmaceutical therapies produce distinct effects on bone remodeling, hematopoietic niches, and marrow reserve that conventional tumor dosimetry cannot fully capture.
In 34 patients, two-year local failure after bone SBRT was 14.1%, while progression-free survival was only 8.8%.
Quality of life remained stable after 30–37.5 Gy in three fractions, while symptomatic patients achieved 59% pain response at 24 weeks.
Across six randomized studies, prophylactic corticosteroids reduced radiation-induced pain-flare risk by 37%, although regimens and safety reporting varied.
Pain should remain central for symptomatic disease, but prevention, function, local control and skeletal events require separate standardized endpoints.
A decision tree model identified interleukin-8, hemoglobin, and lymphocyte count as key survival predictors after palliative radiotherapy.
Single-fraction external beam radiotherapy provided similar pain relief to multifraction treatment in this meta-analysis of malignant bone tumor pain.
Diagnostic computed tomography-based single-fraction radiotherapy was feasible for selected non-spine palliative metastases, with no grade 3 or higher acute toxicity.
Single-fraction proton treatment produced pain responses without grade 2 or higher related toxicity in 10 patients with thoracic bone metastases.